Annabelle Ayame Okada (Annabelle A Okada)
Publication Activity (10 Years)
Years Active: 2018-2024
Publications (10 Years): 11
Publications (10 Years): 11
Kyorin University School of Medicine
Affiliation History
Kyorin University School of Medicine
Japan
Professor :: Ophthalmology
Publications
- Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Haruka Ochi, Keisuke Iwasaki, Annabelle Ayame Okada, null nullEfficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
- Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Haruka Ochi, Keisuke Iwasaki, Annabelle Ayame Okada, null nullEfficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
- Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Haruka Ochi, Keisuke Iwasaki, Annabelle Ayame Okada, null nullEfficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024)
- Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Haruka Ochi, Keisuke Iwasaki, Annabelle Ayame Okada, null nullEfficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
- Hideki Koizumi, Fumi Gomi, Akitaka Tsujikawa, Shigeru Honda, Ryusaburo Mori, Haruka Ochi, Keisuke Iwasaki, Annabelle Ayame Okada, null nullEfficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
- Hiroshi Keino, Takuto Aman, Ryota Furuya, Makiko Nakayama, Annabelle Ayame Okada, Wataru Sunayama, Yuji Hatanaka
- Annabelle Ayame Okada, Kanji Takahashi, Masahito Ohji, SungChul Charles Moon, Tobias Machewitz, Koji Sasaki, null null
- Makiko Nakayama, Annabelle Ayame Okada, Isami Hayashi, Hiroshi Keino
- Jean-François Korobelnik, Anat Loewenstein, Bora Eldem, Antonia M Joussen, Adrian Koh, George N Lambrou, Paolo Lanzetta, Xiaoxin Li, Monica Lövestam-Adrian, Rafael Navarro, Annabelle Ayame Okada, Ian Pearce, Francisco J Rodríguez, David T Wong, Lihteh Wu
- Massimo Accorinti, Annabelle Ayame Okada, Justine R Smith, Marta Gilardi
- Tomoko Ohno, Akira Meguro, Masaki Takeuchi, Takahiro Yamane, Takeshi Teshigawara, Nobuyoshi Kitaichi, Yukihiro Horie, Kenichi Namba, Shigeaki Ohno, Kumiko Nakao, Taiji Sakamoto, Tsutomu Sakai, Tadashi Nakano, Hiroshi Keino, Annabelle Ayame Okada, Atsunobu Takeda, Takako Fukuhara, Hisashi Mashimo, Nobuyuki Ohguro, Shinichirou Oono, Hiroshi Enaida, Satoshi Okinami, Nobuhisa Mizuki